Acupuncture anesthesia

Gene symbol: FOXO1

Also known as: FKH1; FKHR; FOXO1A

Organism: Homo sapiens

Summary: This gene belongs to the forkhead family of transcription factors which are characterized by a distinct forkhead domain. The specific function of this gene has not yet been determined; however, it may play a role in myogenic growth and differentiation. Translocation of this gene with PAX3 has been associated with alveolar rhabdomyosarcoma. [provided by RefSeq, Jul 2008]

NCBI gene ID: 2308 Ensembl:ENSG00000150907 MIM:136533 AllianceGenome:HGNC:3819

GO Annotation

Category	Term ID	Term description
Process	GO:0000122	Negative regulation of transcription by RNA polymerase II
Process	GO:0001568	Blood vessel development
Process	GO:0001659	Temperature homeostasis
Process	GO:0001678	Cellular glucose homeostasis
Process	GO:0001944	Vasculature development
Process	GO:0002791	Regulation of peptide secretion
Process	GO:0002792	Negative regulation of peptide secretion
Process	GO:0006109	Regulation of carbohydrate metabolic process
Process	GO:0006111	Regulation of gluconeogenesis
Process	GO:0006355	Regulation of transcription, DNA-templated
Process	GO:0006357	Regulation of transcription by RNA polymerase II
Process	GO:0006473	Protein acetylation
Process	GO:0006807	Nitrogen compound metabolic process
Process	GO:0006914	Autophagy
Process	GO:0006915	Apoptotic process
Process	GO:0006950	Response to stress
Process	GO:0006974	Cellular response to DNA damage stimulus
Process	GO:0006979	Response to oxidative stress
Process	GO:0007154	Cell communication
Process	GO:0007165	Signal transduction
Process	GO:0007166	Cell surface receptor signaling pathway
Process	GO:0007167	Enzyme-linked receptor protein signaling pathway
Process	GO:0007169	Transmembrane receptor protein tyrosine kinase signaling pathway
Process	GO:0007267	Cell-cell signaling
Process	GO:0007275	Multicellular organism development
Process	GO:0008152	Metabolic process
Process	GO:0008219	Cell death
Process	GO:0008286	Insulin receptor signaling pathway
Process	GO:0009056	Catabolic process
Process	GO:0009266	Response to temperature stimulus
Process	GO:0009267	Cellular response to starvation
Process	GO:0009409	Response to cold
Process	GO:0009605	Response to external stimulus
Process	GO:0009628	Response to abiotic stimulus
Process	GO:0009719	Response to endogenous stimulus
Process	GO:0009725	Response to hormone
Process	GO:0009889	Regulation of biosynthetic process
Process	GO:0009890	Negative regulation of biosynthetic process
Process	GO:0009891	Positive regulation of biosynthetic process
Process	GO:0009892	Negative regulation of metabolic process
Process	GO:0009893	Positive regulation of metabolic process
Process	GO:0009894	Regulation of catabolic process
Process	GO:0009896	Positive regulation of catabolic process
Process	GO:0009966	Regulation of signal transduction
Process	GO:0009968	Negative regulation of signal transduction
Process	GO:0009987	Cellular process
Process	GO:0009991	Response to extracellular stimulus
Process	GO:0010033	Response to organic substance
Process	GO:0010035	Response to inorganic substance
Process	GO:0010243	Response to organonitrogen compound
Process	GO:0010468	Regulation of gene expression
Process	GO:0010506	Regulation of autophagy
Process	GO:0010508	Positive regulation of autophagy
Process	GO:0010556	Regulation of macromolecule biosynthetic process
Process	GO:0010557	Positive regulation of macromolecule biosynthetic process
Process	GO:0010558	Negative regulation of macromolecule biosynthetic process
Process	GO:0010604	Positive regulation of macromolecule metabolic process
Process	GO:0010605	Negative regulation of macromolecule metabolic process
Process	GO:0010611	Regulation of cardiac muscle hypertrophy
Process	GO:0010612	Regulation of cardiac muscle adaptation
Process	GO:0010614	Negative regulation of cardiac muscle hypertrophy
Process	GO:0010616	Negative regulation of cardiac muscle adaptation
Process	GO:0010646	Regulation of cell communication
Process	GO:0010648	Negative regulation of cell communication
Process	GO:0010675	Regulation of cellular carbohydrate metabolic process
Process	GO:0010676	Positive regulation of cellular carbohydrate metabolic process
Process	GO:0010817	Regulation of hormone levels
Process	GO:0010906	Regulation of glucose metabolic process
Process	GO:0010907	Positive regulation of glucose metabolic process
Process	GO:0010941	Regulation of cell death
Process	GO:0010942	Positive regulation of cell death
Process	GO:0012501	Programmed cell death
Process	GO:0014741	Negative regulation of muscle hypertrophy
Process	GO:0014743	Regulation of muscle hypertrophy
Process	GO:0014745	Negative regulation of muscle adaptation
Process	GO:0016055	Wnt signaling pathway
Process	GO:0019219	Regulation of nucleobase-containing compound metabolic process
Process	GO:0019222	Regulation of metabolic process
Process	GO:0019538	Protein metabolic process
Process	GO:0019725	Cellular homeostasis
Process	GO:0019827	Stem cell population maintenance
Process	GO:0023051	Regulation of signaling
Process	GO:0023052	Signaling
Process	GO:0023057	Negative regulation of signaling
Process	GO:0030111	Regulation of Wnt signaling pathway
Process	GO:0030154	Cell differentiation
Process	GO:0030178	Negative regulation of Wnt signaling pathway
Process	GO:0031323	Regulation of cellular metabolic process
Process	GO:0031324	Negative regulation of cellular metabolic process
Process	GO:0031325	Positive regulation of cellular metabolic process
Process	GO:0031326	Regulation of cellular biosynthetic process
Process	GO:0031327	Negative regulation of cellular biosynthetic process
Process	GO:0031328	Positive regulation of cellular biosynthetic process
Process	GO:0031329	Regulation of cellular catabolic process
Process	GO:0031331	Positive regulation of cellular catabolic process
Process	GO:0031667	Response to nutrient levels
Process	GO:0031668	Cellular response to extracellular stimulus
Process	GO:0031669	Cellular response to nutrient levels
Process	GO:0032501	Multicellular organismal process
Process	GO:0032502	Developmental process
Process	GO:0032868	Response to insulin
Process	GO:0032869	Cellular response to insulin stimulus
Process	GO:0032870	Cellular response to hormone stimulus
Process	GO:0032872	Regulation of stress-activated MAPK cascade
Process	GO:0032873	Negative regulation of stress-activated MAPK cascade
Process	GO:0032879	Regulation of localization
Process	GO:0032880	Regulation of protein localization
Process	GO:0033500	Carbohydrate homeostasis
Process	GO:0033554	Cellular response to stress
Process	GO:0033993	Response to lipid
Process	GO:0034599	Cellular response to oxidative stress
Process	GO:0036211	Protein modification process
Process	GO:0036295	Cellular response to increased oxygen levels
Process	GO:0036296	Response to increased oxygen levels
Process	GO:0042127	Regulation of cell population proliferation
Process	GO:0042176	Regulation of protein catabolic process
Process	GO:0042221	Response to chemical
Process	GO:0042592	Homeostatic process
Process	GO:0042593	Glucose homeostasis
Process	GO:0042594	Response to starvation
Process	GO:0042981	Regulation of apoptotic process
Process	GO:0043065	Positive regulation of apoptotic process
Process	GO:0043066	Negative regulation of apoptotic process
Process	GO:0043067	Regulation of programmed cell death
Process	GO:0043068	Positive regulation of programmed cell death
Process	GO:0043069	Negative regulation of programmed cell death
Process	GO:0043170	Macromolecule metabolic process
Process	GO:0043255	Regulation of carbohydrate biosynthetic process
Process	GO:0043408	Regulation of MAPK cascade
Process	GO:0043409	Negative regulation of MAPK cascade
Process	GO:0043412	Macromolecule modification
Process	GO:0043434	Response to peptide hormone
Process	GO:0043502	Regulation of muscle adaptation
Process	GO:0043543	Protein acylation
Process	GO:0044057	Regulation of system process
Process	GO:0044237	Cellular metabolic process
Process	GO:0044238	Primary metabolic process
Process	GO:0044248	Cellular catabolic process
Process	GO:0045444	Fat cell differentiation
Process	GO:0045595	Regulation of cell differentiation
Process	GO:0045596	Negative regulation of cell differentiation
Process	GO:0045598	Regulation of fat cell differentiation
Process	GO:0045599	Negative regulation of fat cell differentiation
Process	GO:0045722	Positive regulation of gluconeogenesis
Process	GO:0045732	Positive regulation of protein catabolic process
Process	GO:0045892	Negative regulation of transcription, DNA-templated
Process	GO:0045893	Positive regulation of transcription, DNA-templated
Process	GO:0045913	Positive regulation of carbohydrate metabolic process
Process	GO:0045934	Negative regulation of nucleobase-containing compound metabolic process
Process	GO:0045935	Positive regulation of nucleobase-containing compound metabolic process
Process	GO:0045944	Positive regulation of transcription by RNA polymerase II
Process	GO:0046676	Negative regulation of insulin secretion
Process	GO:0046883	Regulation of hormone secretion
Process	GO:0046888	Negative regulation of hormone secretion
Process	GO:0048518	Positive regulation of biological process
Process	GO:0048519	Negative regulation of biological process
Process	GO:0048522	Positive regulation of cellular process
Process	GO:0048523	Negative regulation of cellular process
Process	GO:0048583	Regulation of response to stimulus
Process	GO:0048585	Negative regulation of response to stimulus
Process	GO:0048731	System development
Process	GO:0048856	Anatomical structure development
Process	GO:0048869	Cellular developmental process
Process	GO:0048871	Multicellular organismal homeostasis
Process	GO:0048878	Chemical homeostasis
Process	GO:0050708	Regulation of protein secretion
Process	GO:0050709	Negative regulation of protein secretion
Process	GO:0050789	Regulation of biological process
Process	GO:0050793	Regulation of developmental process
Process	GO:0050794	Regulation of cellular process
Process	GO:0050796	Regulation of insulin secretion
Process	GO:0050896	Response to stimulus
Process	GO:0051046	Regulation of secretion
Process	GO:0051048	Negative regulation of secretion
Process	GO:0051049	Regulation of transport
Process	GO:0051051	Negative regulation of transport
Process	GO:0051093	Negative regulation of developmental process
Process	GO:0051171	Regulation of nitrogen compound metabolic process
Process	GO:0051172	Negative regulation of nitrogen compound metabolic process
Process	GO:0051173	Positive regulation of nitrogen compound metabolic process
Process	GO:0051223	Regulation of protein transport
Process	GO:0051224	Negative regulation of protein transport
Process	GO:0051239	Regulation of multicellular organismal process
Process	GO:0051241	Negative regulation of multicellular organismal process
Process	GO:0051246	Regulation of protein metabolic process
Process	GO:0051247	Positive regulation of protein metabolic process
Process	GO:0051252	Regulation of RNA metabolic process
Process	GO:0051253	Negative regulation of RNA metabolic process
Process	GO:0051254	Positive regulation of RNA metabolic process
Process	GO:0051716	Cellular response to stimulus
Process	GO:0055082	Cellular chemical homeostasis
Process	GO:0055093	Response to hyperoxia
Process	GO:0060070	Canonical Wnt signaling pathway
Process	GO:0060255	Regulation of macromolecule metabolic process
Process	GO:0060341	Regulation of cellular localization
Process	GO:0060548	Negative regulation of cell death
Process	GO:0060828	Regulation of canonical Wnt signaling pathway
Process	GO:0061919	Process utilizing autophagic mechanism
Process	GO:0062012	Regulation of small molecule metabolic process
Process	GO:0062013	Positive regulation of small molecule metabolic process
Process	GO:0062197	Cellular response to chemical stress
Process	GO:0065007	Biological regulation
Process	GO:0065008	Regulation of biological quality
Process	GO:0070201	Regulation of establishment of protein localization
Process	GO:0070302	Regulation of stress-activated protein kinase signaling cascade
Process	GO:0070303	Negative regulation of stress-activated protein kinase signaling cascade
Process	GO:0070417	Cellular response to cold
Process	GO:0070482	Response to oxygen levels
Process	GO:0070542	Response to fatty acid
Process	GO:0070887	Cellular response to chemical stimulus
Process	GO:0071241	Cellular response to inorganic substance
Process	GO:0071310	Cellular response to organic substance
Process	GO:0071375	Cellular response to peptide hormone stimulus
Process	GO:0071417	Cellular response to organonitrogen compound
Process	GO:0071453	Cellular response to oxygen levels
Process	GO:0071455	Cellular response to hyperoxia
Process	GO:0071495	Cellular response to endogenous stimulus
Process	GO:0071496	Cellular response to external stimulus
Process	GO:0071704	Organic substance metabolic process
Process	GO:0071731	Response to nitric oxide
Process	GO:0071732	Cellular response to nitric oxide
Process	GO:0072359	Circulatory system development
Process	GO:0080090	Regulation of primary metabolic process
Process	GO:0080134	Regulation of response to stress
Process	GO:0080135	Regulation of cellular response to stress
Process	GO:0090087	Regulation of peptide transport
Process	GO:0090090	Negative regulation of canonical Wnt signaling pathway
Process	GO:0090257	Regulation of muscle system process
Process	GO:0090276	Regulation of peptide hormone secretion
Process	GO:0090278	Negative regulation of peptide hormone secretion
Process	GO:0097009	Energy homeostasis
Process	GO:0097150	Neuronal stem cell population maintenance
Process	GO:0098727	Maintenance of cell number
Process	GO:0198738	Cell-cell signaling by wnt
Process	GO:1901564	Organonitrogen compound metabolic process
Process	GO:1901652	Response to peptide
Process	GO:1901653	Cellular response to peptide
Process	GO:1901698	Response to nitrogen compound
Process	GO:1901699	Cellular response to nitrogen compound
Process	GO:1901700	Response to oxygen-containing compound
Process	GO:1901701	Cellular response to oxygen-containing compound
Process	GO:1902170	Cellular response to reactive nitrogen species
Process	GO:1902531	Regulation of intracellular signal transduction
Process	GO:1902532	Negative regulation of intracellular signal transduction
Process	GO:1902679	Negative regulation of RNA biosynthetic process
Process	GO:1902680	Positive regulation of RNA biosynthetic process
Process	GO:1903242	Regulation of cardiac muscle hypertrophy in response to stress
Process	GO:1903243	Negative regulation of cardiac muscle hypertrophy in response to stress
Process	GO:1903506	Regulation of nucleic acid-templated transcription
Process	GO:1903507	Negative regulation of nucleic acid-templated transcription
Process	GO:1903508	Positive regulation of nucleic acid-templated transcription
Process	GO:1903530	Regulation of secretion by cell
Process	GO:1903531	Negative regulation of secretion by cell
Process	GO:1903828	Negative regulation of protein localization
Process	GO:1904950	Negative regulation of establishment of protein localization
Process	GO:1905114	Cell surface receptor signaling pathway involved in cell-cell signaling
Process	GO:2000177	Regulation of neural precursor cell proliferation
Process	GO:2000377	Regulation of reactive oxygen species metabolic process
Process	GO:2001141	Regulation of RNA biosynthetic process
Component	GO:0000785	Chromatin
Component	GO:0005622	Intracellular anatomical structure
Component	GO:0005634	Nucleus
Component	GO:0005654	Nucleoplasm
Component	GO:0005694	Chromosome
Component	GO:0005737	Cytoplasm
Component	GO:0005739	Mitochondrion
Component	GO:0005829	Cytosol
Component	GO:0031974	Membrane-enclosed lumen
Component	GO:0031981	Nuclear lumen
Component	GO:0043226	Organelle
Component	GO:0043227	Membrane-bounded organelle
Component	GO:0043228	Non-membrane-bounded organelle
Component	GO:0043229	Intracellular organelle
Component	GO:0043231	Intracellular membrane-bounded organelle
Component	GO:0043232	Intracellular non-membrane-bounded organelle
Component	GO:0043233	Organelle lumen
Component	GO:0070013	Intracellular organelle lumen
Component	GO:0110165	Cellular anatomical entity
Function	GO:0000976	Transcription cis-regulatory region binding
Function	GO:0000977	RNA polymerase II transcription regulatory region sequence-specific DNA binding
Function	GO:0000978	RNA polymerase II cis-regulatory region sequence-specific DNA binding
Function	GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific
Function	GO:0000987	Cis-regulatory region sequence-specific DNA binding
Function	GO:0001067	Transcription regulatory region nucleic acid binding
Function	GO:0001216	DNA-binding transcription activator activity
Function	GO:0001217	DNA-binding transcription repressor activity
Function	GO:0001227	DNA-binding transcription repressor activity, RNA polymerase II-specific
Function	GO:0001228	DNA-binding transcription activator activity, RNA polymerase II-specific
Function	GO:0003676	Nucleic acid binding
Function	GO:0003677	DNA binding
Function	GO:0003682	Chromatin binding
Function	GO:0003690	Double-stranded DNA binding
Function	GO:0003700	DNA-binding transcription factor activity
Function	GO:0005488	Binding
Function	GO:0005515	Protein binding
Function	GO:0008013	Beta-catenin binding
Function	GO:0019899	Enzyme binding
Function	GO:0019902	Phosphatase binding
Function	GO:0019903	Protein phosphatase binding
Function	GO:0031490	Chromatin DNA binding
Function	GO:0031625	Ubiquitin protein ligase binding
Function	GO:0043565	Sequence-specific DNA binding
Function	GO:0044389	Ubiquitin-like protein ligase binding
Function	GO:0051721	Protein phosphatase 2A binding
Function	GO:0097159	Organic cyclic compound binding
Function	GO:0140110	Transcription regulator activity
Function	GO:1901363	Heterocyclic compound binding
Function	GO:1990837	Sequence-specific double-stranded DNA binding
Function	GO:1990841	Promoter-specific chromatin binding

Pathway annotation

Category	Term ID	Term description
RCTM	HSA-1257604	PIP3 activates AKT signaling
RCTM	HSA-1266738	Developmental Biology
RCTM	HSA-1280215	Cytokine Signaling in Immune system
RCTM	HSA-162582	Signal Transduction
RCTM	HSA-1643685	Disease
RCTM	HSA-168256	Immune System
RCTM	HSA-186712	Regulation of beta-cell development
RCTM	HSA-198693	AKT phosphorylates targets in the nucleus
RCTM	HSA-210745	Regulation of gene expression in beta cells
RCTM	HSA-211163	AKT-mediated inactivation of FOXO1A
RCTM	HSA-212436	Generic Transcription Pathway
RCTM	HSA-2219528	PI3K/AKT Signaling in Cancer
RCTM	HSA-449147	Signaling by Interleukins
RCTM	HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers
RCTM	HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer
RCTM	HSA-5683057	MAPK family signaling cascades
RCTM	HSA-5687128	MAPK6/MAPK4 signaling
RCTM	HSA-6785807	Interleukin-4 and Interleukin-13 signaling
RCTM	HSA-73857	RNA Polymerase II Transcription
RCTM	HSA-74160	Gene expression (Transcription)
RCTM	HSA-9006925	Intracellular signaling by second messengers
RCTM	HSA-9614085	FOXO-mediated transcription
RCTM	HSA-9614399	Regulation of localization of FOXO transcription factors
RCTM	HSA-9614657	FOXO-mediated transcription of cell death genes
RCTM	HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
RCTM	HSA-9617629	Regulation of FOXO transcriptional activity by acetylation
RCTM	HSA-9617828	FOXO-mediated transcription of cell cycle genes
WikiPathways	WP138	Androgen receptor signaling pathway
WikiPathways	WP1541	Energy metabolism
WikiPathways	WP2034	Leptin signaling pathway
WikiPathways	WP2035	Follicle stimulating hormone (FSH) signaling pathway
WikiPathways	WP2261	Glioblastoma signaling pathways
WikiPathways	WP23	B cell receptor signaling pathway
WikiPathways	WP2324	AGE/RAGE pathway
WikiPathways	WP236	Adipogenesis
WikiPathways	WP2853	Endoderm differentiation
WikiPathways	WP2875	Constitutive androstane receptor pathway
WikiPathways	WP2876	Pregnane X receptor pathway
WikiPathways	WP2877	Vitamin D receptor pathway
WikiPathways	WP2882	Nuclear receptors meta-pathway
WikiPathways	WP3286	Copper homeostasis
WikiPathways	WP3298	Melatonin metabolism and effects
WikiPathways	WP3303	RAC1/PAK1/p38/MMP2 pathway
WikiPathways	WP3599	Transcription factor regulation in adipogenesis
WikiPathways	WP3630	NAD metabolism, sirtuins and aging
WikiPathways	WP3844	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities
WikiPathways	WP3876	BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation
WikiPathways	WP3888	VEGFA-VEGFR2 signaling
WikiPathways	WP3915	Angiopoietin-like protein 8 regulatory pathway
WikiPathways	WP3932	Focal adhesion: PI3K-Akt-mTOR-signaling pathway
WikiPathways	WP3981	miRNA regulation of prostate cancer signaling pathways
WikiPathways	WP4149	White fat cell differentiation
WikiPathways	WP4186	Somatroph axis (GH) and its relationship to dietary restriction and aging
WikiPathways	WP437	EGF/EGFR signaling pathway
WikiPathways	WP4542	Leukocyte-intrinsic Hippo pathway functions
WikiPathways	WP4659	Gastrin signaling pathway
WikiPathways	WP4746	Thyroid hormones production and peripheral downstream signaling effects
WikiPathways	WP481	Insulin signaling
WikiPathways	WP5044	Kynurenine pathway and links to cell senescence
WikiPathways	WP5066	FOXA2 pathway
WikiPathways	WP5087	Malignant pleural mesothelioma
WikiPathways	WP5092	Interactions of natural killer cells in pancreatic cancer
WikiPathways	WP5180	DYRK1A
WikiPathways	WP5218	Extrafollicular and follicular B cell activation by SARS-CoV-2
WikiPathways	WP5316	Primary ovarian insufficiency
WikiPathways	WP673	ErbB signaling pathway
KEGG	hsa04068	FoxO signaling pathway
KEGG	hsa04152	AMPK signaling pathway
KEGG	hsa04211	Longevity regulating pathway
KEGG	hsa04213	Longevity regulating pathway - multiple species
KEGG	hsa04218	Cellular senescence
KEGG	hsa04910	Insulin signaling pathway
KEGG	hsa04919	Thyroid hormone signaling pathway
KEGG	hsa04922	Glucagon signaling pathway
KEGG	hsa04931	Insulin resistance
KEGG	hsa04933	AGE-RAGE signaling pathway in diabetic complications
KEGG	hsa04936	Alcoholic liver disease
KEGG	hsa05131	Shigellosis
KEGG	hsa05165	Human papillomavirus infection
KEGG	hsa05200	Pathways in cancer
KEGG	hsa05202	Transcriptional misregulation in cancer
KEGG	hsa05215	Prostate cancer

Expression profile of FOXO1 in omics data

ID	GSE101724
Title	Effects of Propofol Treatment in Neural Progenitors Derived from Human Induced Pluripotent Stem Cells
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM2714094	untreated rep1	treatment: untreated	9.117643309
GSM2714095	untreated rep2	treatment: untreated	9.290491252
GSM2714096	20 uM propofol rep1	treatment: 20 uM propofol	9.459573342
GSM2714097	20 uM propofol rep2	treatment: 20 uM propofol	9.38274876
GSM2714098	300 uM propofol rep1	treatment: 300 uM propofol	8.937681185
GSM2714099	300 uM propofol rep2	treatment: 300 uM propofol	9.146704733

ID	GSE120596
Title	Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction is Associated with Differences in Activation of the Cyclooxygenase Pathway
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM3405450	1001_baseline	cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: baseline library barcode: ATTACTCG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	833.0
GSM3405451	1001_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: post-surgery 1 library barcode: TCCGGAGA-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	487.0
GSM3405452	1002_baseline	cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: baseline library barcode: CGCTCATT-TATAGCCT drug treatment: Placebo response group: Placebo	867.0
GSM3405453	1002_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: post-surgery 1 library barcode: GAGATTCC-TATAGCCT drug treatment: Placebo response group: Placebo	570.0
GSM3405454	1003_baseline	cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: baseline library barcode: ATTCAGAA-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder	890.0
GSM3405455	1003_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: post-surgery 1 library barcode: GAATTCGT-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder	821.0
GSM3405456	1004_baseline	cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: baseline library barcode: CTGAAGCT-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	1094.0
GSM3405457	1004_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: post-surgery 1 library barcode: TAATGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder
GSM3405458	1005_baseline	cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: baseline library barcode: CGGCTATG-TATAGCCT drug treatment: Placebo response group: Placebo	1139.0
GSM3405459	1005_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-TATAGCCT drug treatment: Placebo response group: Placebo
GSM3405460	1006_baseline	cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: baseline library barcode: TCTCGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	831.0
GSM3405461	1006_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: post-surgery 1 library barcode: AGCGATAG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	846.0
GSM3405462	1007_baseline	cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: baseline library barcode: ATTACTCG-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405463	1007_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: post-surgery 1 library barcode: TCCGGAGA-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405464	1008_baseline	cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: baseline library barcode: CGCTCATT-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405465	1008_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405466	1008_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405467	1011_baseline	cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: baseline library barcode: GAATTCGT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder	680.0
GSM3405468	1011_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405469	1011_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405470	1012_baseline	cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: baseline library barcode: CGGCTATG-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder	993.0
GSM3405471	1012_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder	981.0
GSM3405472	1012_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder
GSM3405473	1014_baseline	cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: baseline library barcode: AGCGATAG-ATAGAGGC drug treatment: Placebo response group: Placebo	887.0
GSM3405474	1014_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-CCTATCCT drug treatment: Placebo response group: Placebo	868.0
GSM3405475	1014_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-CCTATCCT drug treatment: Placebo response group: Placebo	631.0
GSM3405476	1015_baseline	cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: baseline library barcode: CGCTCATT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1132.0
GSM3405477	1015_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1036.0
GSM3405478	1015_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	945.0
GSM3405479	1016_baseline	cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: baseline library barcode: GAATTCGT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1265.0
GSM3405480	1016_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1045.0
GSM3405481	1016_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1088.0
GSM3405482	1017_baseline	cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: baseline library barcode: CGGCTATG-CCTATCCT drug treatment: Placebo response group: Placebo	773.0
GSM3405483	1017_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-CCTATCCT drug treatment: Placebo response group: Placebo	831.0
GSM3405484	1017_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 2 library barcode: TCTCGCGC-CCTATCCT drug treatment: Placebo response group: Placebo	912.0
GSM3405485	1018_baseline	cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: baseline library barcode: AGCGATAG-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1613.0
GSM3405486	1018_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	1449.0
GSM3405487	1018_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	1255.0
GSM3405488	1019_baseline	cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: baseline library barcode: CGCTCATT-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	1051.0
GSM3405489	1019_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	1621.0
GSM3405490	1019_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	864.0
GSM3405491	1020_baseline	cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: baseline library barcode: GAATTCGT-GGCTCTGA drug treatment: Placebo response group: Placebo
GSM3405492	1020_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-GGCTCTGA drug treatment: Placebo response group: Placebo	968.0
GSM3405493	1020_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-GGCTCTGA drug treatment: Placebo response group: Placebo	1051.0
GSM3405494	1021_baseline	cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: baseline library barcode: CGGCTATG-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder	639.0
GSM3405495	1021_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder	681.0
GSM3405496	1021_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder	572.0
GSM3405497	1022_baseline	cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: baseline library barcode: AGCGATAG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	1281.0
GSM3405498	1022_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder	981.0
GSM3405499	1022_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder	1506.0
GSM3405500	1023_baseline	cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: baseline library barcode: CGCTCATT-AGGCGAAG drug treatment: Placebo response group: Placebo	1150.0
GSM3405501	1023_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-AGGCGAAG drug treatment: Placebo response group: Placebo	800.0
GSM3405502	1023_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-AGGCGAAG drug treatment: Placebo response group: Placebo	715.0
GSM3405503	1024_baseline	cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: baseline library barcode: GAATTCGT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder	1177.0
GSM3405504	1024_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder	1271.0
GSM3405505	1024_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder	868.0
GSM3405506	1026_baseline	cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: baseline library barcode: CGGCTATG-AGGCGAAG drug treatment: Placebo response group: Placebo	1013.0
GSM3405507	1026_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-AGGCGAAG drug treatment: Placebo response group: Placebo	950.0
GSM3405508	1026_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-AGGCGAAG drug treatment: Placebo response group: Placebo	833.0
GSM3405509	1027_baseline	cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: baseline library barcode: AGCGATAG-AGGCGAAG drug treatment: Placebo response group: Placebo	1067.0
GSM3405510	1027_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-TAATCTTA drug treatment: Placebo response group: Placebo	1014.0
GSM3405511	1027_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-TAATCTTA drug treatment: Placebo response group: Placebo	800.0
GSM3405512	1028_baseline	cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: baseline library barcode: CGCTCATT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	871.0
GSM3405513	1028_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	821.0
GSM3405514	1028_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	862.0
GSM3405515	1029_baseline	cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: baseline library barcode: GAATTCGT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	683.0
GSM3405516	1029_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	499.0
GSM3405517	1029_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	526.0
GSM3405518	1030_baseline	cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: baseline library barcode: CGGCTATG-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	912.0
GSM3405519	1030_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	985.0
GSM3405520	1030_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	802.0
GSM3405521	1032_baseline	cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: baseline library barcode: AGCGATAG-TAATCTTA drug treatment: Placebo response group: Placebo	1332.0
GSM3405522	1032_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-CAGGACGT drug treatment: Placebo response group: Placebo	1285.0
GSM3405523	1032_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-CAGGACGT drug treatment: Placebo response group: Placebo	1250.0
GSM3405524	1033_baseline	cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: baseline library barcode: CGCTCATT-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder	966.0
GSM3405525	1033_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder	1107.0
GSM3405526	1033_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder	990.0

ID	GSE12860
Title	Antirheumatic Drug Response in Human Chondrocytes: Potential Molecular Targets to Stimulate Cartilage Regeneration
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM322609	RASF stimulated chondrocytes rep 1 GSM253283	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium	7.398045376000001
GSM322610	RASF stimulated chondrocytes rep 2 GSM253284	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium	7.210532300000001
GSM322611	NDSF stimulated chondrocytes rep 1 GSM253285	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium	7.068038091
GSM322612	NDSF stimulated chondrocytes rep 2 GSM253286	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium	7.153831574
GSM322613	Chondrocytes stimulated with diclofenac treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h	6.153774473
GSM322614	Chondrocytes stimulated with diclofenac treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h	6.6160459215
GSM322615	Chondrocytes stimulated with prioxicam treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h	6.548832377
GSM322616	Chondrocytes stimulated with prioxicam treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h	6.529364022999999
GSM322617	Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h	7.1542411585
GSM322618	Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h	7.0312460495
GSM322619	Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h	6.6470460515
GSM322620	Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h	6.586736044
GSM322621	Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h	6.727772334
GSM322622	Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h	6.7816349215
GSM322623	Chondrocytes stimulated with methotrexate treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h	6.7836897405
GSM322624	Chondrocytes stimulated with methotrexate treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h	6.710672591
GSM322625	Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h	7.6008382789999995
GSM322626	Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h	7.530771192
GSM322627	Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h	8.019646401
GSM322628	Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h	7.6845993855

ID	GSE150408
Title	Identification of key genes potentially related to intervertebral disc degeneration by microarray analysis
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM4548691	volunteer-9	tissue: whole blood diagnosis: healthy control treatment: n/a	7.685837816
GSM4548692	volunteer-10	tissue: whole blood diagnosis: healthy control treatment: n/a	8.054875032
GSM4548693	volunteer-11	tissue: whole blood diagnosis: healthy control treatment: n/a	8.052060401
GSM4548694	volunteer-12	tissue: whole blood diagnosis: healthy control treatment: n/a	8.542047585
GSM4548695	volunteer-13	tissue: whole blood diagnosis: healthy control treatment: n/a	7.503834167
GSM4548696	volunteer-14	tissue: whole blood diagnosis: healthy control treatment: n/a	7.918809559
GSM4548697	volunteer-15	tissue: whole blood diagnosis: healthy control treatment: n/a	8.304095094
GSM4548698	volunteer-16	tissue: whole blood diagnosis: healthy control treatment: n/a	8.368947185
GSM4548699	volunteer-17	tissue: whole blood diagnosis: healthy control treatment: n/a	8.135736644
GSM4548700	volunteer-18	tissue: whole blood diagnosis: healthy control treatment: n/a	8.422538201
GSM4548701	volunteer-19	tissue: whole blood diagnosis: healthy control treatment: n/a	8.085101524
GSM4548702	volunteer-20	tissue: whole blood diagnosis: healthy control treatment: n/a	7.970276551
GSM4548703	volunteer-21	tissue: whole blood diagnosis: healthy control treatment: n/a	7.523029894
GSM4548704	volunteer-22	tissue: whole blood diagnosis: healthy control treatment: n/a	8.87039137
GSM4548705	volunteer-23	tissue: whole blood diagnosis: healthy control treatment: n/a	8.958587023
GSM4548706	volunteer-24	tissue: whole blood diagnosis: healthy control treatment: n/a	8.782315886
GSM4548707	volunteer-25	tissue: whole blood diagnosis: healthy control treatment: n/a	9.034115821
GSM4548708	patient-9	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.220053625
GSM4548709	patient-10	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.303079203
GSM4548710	patient-11	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.937511477
GSM4548711	patient-12	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.893960416
GSM4548712	patient-13	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.843854157
GSM4548713	patient-14	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.248255417
GSM4548714	patient-15	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.163212949
GSM4548715	patient-16	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.053120429
GSM4548716	patient-17	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.670500418
GSM4548717	patient-18	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.238413793
GSM4548718	patient-19	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.806090738
GSM4548719	patient-20	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.482179789
GSM4548720	patient-21	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.809342509
GSM4548721	patient-22	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	9.184718869
GSM4548722	patient-23	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.343931048
GSM4548723	patient-24	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.761176757
GSM4548724	patient-25	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.560324885
GSM4548725	treatment-1	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.170983611
GSM4548726	treatment-2	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.396951774
GSM4548727	treatment-3	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.785185668
GSM4548728	treatment-4	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.016097289
GSM4548729	treatment-5	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.146813965
GSM4548730	treatment-6	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.085873736
GSM4548731	treatment-7	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.215835935
GSM4548732	treatment-8	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.041389356
GSM4548733	treatment-9	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.842693987
GSM4548734	treatment-10	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.791194921
GSM4548735	treatment-11	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.008899703
GSM4548736	treatment-12	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.373343894
GSM4548737	treatment-13	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.954993672
GSM4548738	treatment-14	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	9.301252835
GSM4548739	treatment-15	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.760172053
GSM4548740	treatment-16	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	9.050285186
GSM4548741	treatment-17	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	9.028497262
GSM4548742	treatment-18	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.655676246
GSM4548743	treatment-19	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.745528156
GSM4548744	treatment-20	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.934859388
GSM4548745	treatment-21	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.99419788
GSM4548746	treatment-22	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.077395593
GSM4548747	treatment-23	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.910736848
GSM4548748	treatment-24	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.683670033
GSM4548749	treatment-25	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.748876386

ID	GSE166193
Title	Expression data from human astrocytes (HA) under oxygen-glucose deprivation / reoxygenation
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM5065655	without DEX pretreatment, reoxygenation time is 0 h	cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 0 h tissue: brain	6.5988
GSM5065656	without DEX pretreatment, reoxygenation time is 2 h	cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 2 h tissue: brain	7.35002
GSM5065657	without DEX pretreatment, reoxygenation time is 6 h	cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 6 h tissue: brain	6.97214
GSM5065658	without DEX pretreatment, reoxygenation time is 12 h	cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 12 h tissue: brain	7.10746
GSM5065659	without DEX pretreatment, reoxygenation time is 24 h	cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 24 h tissue: brain	7.08723
GSM5065660	with DEX pretreatment, reoxygenation time is 0 h	cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 0 h tissue: brain	7.08104
GSM5065661	with DEX pretreatment, reoxygenation time is 2 h	cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 2 h tissue: brain	7.47044
GSM5065662	with DEX pretreatment, reoxygenation time is 6 h	cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 6 h tissue: brain	7.04413
GSM5065663	with DEX pretreatment, reoxygenation time is 12 h	cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 12 h tissue: brain	7.4796
GSM5065664	with DEX pretreatment, reoxygenation time is 24 h	cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 24 h tissue: brain	6.97199
GSM5065665	control	cell type: astrocyte treatment: without stress tissue: brain	7.51668

ID	GSE179004
Title	Expression data from glioblastoma surgical specimens
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM5403447	glioblastoma tissue 1 in TIVA group	tissue: glioblastoma	2.552403622
GSM5403448	glioblastoma tissue 2 in TIVA group	tissue: glioblastoma	3.9877110499999997
GSM5403449	glioblastoma tissue 3 in TIVA group	tissue: glioblastoma	4.0862203945
GSM5403450	glioblastoma tissue 1 in INHA group	tissue: glioblastoma	3.5779253925
GSM5403451	glioblastoma tissue 2 in INHA group	tissue: glioblastoma	4.4383383
GSM5403452	glioblastoma tissue 3 in INHA group	tissue: glioblastoma	3.839997645

ID	GSE212044
Title	Reversibility of etomidate-induced contractile arrest through activation of myocardial autophagy
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM6508421	IPSC-CM cells, DSMO 1	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30	427.0
GSM6508422	IPSC-CM cells, DSMO 2	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30	402.0
GSM6508423	IPSC-CM cells, DSMO 3	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30	455.0
GSM6508424	IPSC-CM cells, Etomidate 1	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30	402.0
GSM6508425	IPSC-CM cells, Etomidate 2	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30	134.0
GSM6508426	IPSC-CM cells, Etomidate 3	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30	490.0
GSM6508427	IPSC-CM cells, Propofol 1	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30	366.0
GSM6508428	IPSC-CM cells, Propofol 2	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30	398.0
GSM6508429	IPSC-CM cells, Propofol 3	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30	389.0

ID	GSE255952
Title	Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM8083291	patient C1P1, before first course of MP, T cells	tissue: peripheral blood patient id: C1P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 34.9 cells per ml: 2982000 purity (%): 98.1 rna integrity number: 7.8 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss	12.67503
GSM8083292	patient C1P1, after first course of MP, T cells	tissue: peripheral blood patient id: C1P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 25.9 cells per ml: 304500 purity (%): 95.3 rna integrity number: 8.7 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss	12.38785
GSM8083293	patient C1P1, before second course of MP, T cells	tissue: peripheral blood patient id: C1P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.8 cells per ml: 1254750 purity (%): 96.7 rna integrity number: 8.3 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea	12.63022
GSM8083294	patient C1P1, after second course of MP, T cells	tissue: peripheral blood patient id: C1P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.6 cells per ml: 231000 purity (%): 93.7 rna integrity number: 9.4 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea	12.00121
GSM8083295	patient C1P2, before first course of MP, B cells	tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 4.7 cells per ml: 236250 purity (%): 91.9 rna integrity number: 9.0 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	11.62039
GSM8083296	patient C1P2, after first course of MP, B cells	tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 3.7 cells per ml: 283500 purity (%): 91.0 rna integrity number: 9.1 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	11.13209
GSM8083297	patient C1P2, before first course of MP, T cells	tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 28.7 cells per ml: 693000 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	12.69237
GSM8083298	patient C1P2, after first course of MP, T cells	tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.5 cells per ml: 624750 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	12.47845
GSM8083299	patient C1P3, before first course of MP, B cells	tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 10.0 cells per ml: 498750 purity (%): 98.8 rna integrity number: 8.9 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	11.93943
GSM8083300	patient C1P3, after first course of MP, B cells	tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.7 cells per ml: 383250 purity (%): 97.9 rna integrity number: 9.4 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	11.34448
GSM8083301	patient C1P3, before first course of MP, T cells	tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 31.0 cells per ml: 1134000 purity (%): 94.7 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	12.26694
GSM8083302	patient C1P3, after first course of MP, T cells	tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 18.1 cells per ml: 640500 purity (%): 96.2 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	11.68604
GSM8083303	patient C1P3, before second course of MP, T cells	tissue: peripheral blood patient id: C1P3 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 30.3 cells per ml: 897750 purity (%): 97.0 rna integrity number: 8.5 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp	12.2834
GSM8083304	patient C1P3, after second course of MP, T cells	tissue: peripheral blood patient id: C1P3 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.7 cells per ml: 1433250 purity (%): 97.5 rna integrity number: 8.3 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 5 side effects to mp: none	11.96379
GSM8083305	patient C1P4, before first course of MP, B cells	tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.3 cells per ml: 378000 purity (%): 96.3 rna integrity number: 9.6 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	12.27989
GSM8083306	patient C1P4, after first course of MP, B cells	tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.5 cells per ml: 939750 purity (%): 96.7 rna integrity number: 8.8 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	12.0564
GSM8083307	patient C1P4, before first course of MP, T cells	tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 38.1 cells per ml: 1522500 purity (%): 98.7 rna integrity number: NA age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	13.06978
GSM8083308	patient C1P4, after first course of MP, T cells	tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 15.9 cells per ml: 1617000 purity (%): 98.3 rna integrity number: 8.5 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	11.92632
GSM8083309	patient C1P5, before first course of MP, T cells	tissue: peripheral blood patient id: C1P5 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 31.6 cells per ml: 1344000 purity (%): 99.1 rna integrity number: 8.0 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none	11.95233
GSM8083310	patient C1P5, after first course of MP, T cells	tissue: peripheral blood patient id: C1P5 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 21.9 cells per ml: 1165500 purity (%): 98.9 rna integrity number: 8.4 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none	12.10918
GSM8083311	patient C1P5, before second course of MP, T cells	tissue: peripheral blood patient id: C1P5 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 26.9 cells per ml: 1233750 purity (%): 97.8 rna integrity number: 8.5 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems	11.79063
GSM8083312	patient C1P5, after second course of MP, T cells	tissue: peripheral blood patient id: C1P5 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.0 cells per ml: 514500 purity (%): 98.6 rna integrity number: 8.7 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems	12.06746
GSM8083313	patient C2P1, before first course of MP, B cells	tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 11.7 cells per ml: 2604000 purity (%): 96.7 rna integrity number: 8.5 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.26746
GSM8083314	patient C2P1, after first course of MP, B cells	tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 8.8 cells per ml: 630000 purity (%): 97.4 rna integrity number: 8.4 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.26946
GSM8083315	patient C2P1, before first course of MP, T cells	tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 41.5 cells per ml: 2436000 purity (%): 94.6 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.80123
GSM8083316	patient C2P1, after first course of MP, T cells	tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.2 cells per ml: 346500 purity (%): 86.5 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.24361
GSM8083317	patient C2P2, before first course of MP, B cells	tissue: peripheral blood patient id: C2P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.9 cells per ml: 467250 purity (%): 87.3 rna integrity number: 8.8 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	10.83024
GSM8083318	patient C2P2, after first course of MP, B cells	tissue: peripheral blood patient id: C2P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.3 cells per ml: 199500 purity (%): 97.6 rna integrity number: 9.5 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: 1.5 disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	10.43142
GSM8083319	patient C2P3, before first course of MP, B cells	tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	11.36261
GSM8083320	patient C2P3, after first course of MP, B cells	tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	11.5105
GSM8083321	patient C2P3, before first course of MP, T cells	tissue: peripheral blood patient id: C2P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 20.2 cells per ml: 1711500 purity (%): 94.3 rna integrity number: 7.3 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.02561
GSM8083322	patient C2P3, after first course of MP, T cells	tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 22.8 cells per ml: 992250 purity (%): 96.5 rna integrity number: 8.2 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.66411
GSM8083323	patient C2P4, before first course of MP, B cells	tissue: peripheral blood patient id: C2P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 8.0 cells per ml: 1690500 purity (%): 96.3 rna integrity number: 9.0 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.01005
GSM8083324	patient C2P4, after first course of MP, B cells	tissue: peripheral blood patient id: C2P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 2.2 cells per ml: 273000 purity (%): 93.0 rna integrity number: 8.3 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.1409
GSM8083325	patient C2P5, before first course of MP, B cells	tissue: peripheral blood patient id: C2P5 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.6 cells per ml: 136500 purity (%): 53.8 rna integrity number: 6.9 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	10.07574
GSM8083326	patient C2P5, after first course of MP, B cells	tissue: peripheral blood patient id: C2P5 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.8 cells per ml: 687750 purity (%): 98.1 rna integrity number: 8.2 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	11.09091
GSM8083327	patient C2P6, before first course of MP, B cells	tissue: peripheral blood patient id: C2P6 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 4.2 cells per ml: 546000 purity (%): 92.4 rna integrity number: 8.8 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: 6.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.48804
GSM8083328	patient C2P6, after first course of MP, B cells	tissue: peripheral blood patient id: C2P6 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 6.6 cells per ml: 714000 purity (%): 97.8 rna integrity number: 9.0 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: NA disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	12.74572
GSM8083329	patient C2P7, before first course of MP, B cells	tissue: peripheral blood patient id: C2P7 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.7 cells per ml: 215250 purity (%): 95.6 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: yes fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none	11.51459
GSM8083330	patient C2P7, after first course of MP, B cells	tissue: peripheral blood patient id: C2P7 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.8 cells per ml: 162750 purity (%): 93.2 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: better fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none	10.00694
GSM8083331	patient C2P8, before first course of MP, B cells	tissue: peripheral blood patient id: C2P8 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 3.5 cells per ml: 220500 purity (%): 95.5 rna integrity number: 8.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	10.91271
GSM8083332	patient C2P8, after first course of MP, B cells	tissue: peripheral blood patient id: C2P8 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 11.0 cells per ml: 535500 purity (%): 97.3 rna integrity number: 7.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	11.66328
GSM8083333	patient C3P1, before second course of MP, T cells	tissue: peripheral blood patient id: C3P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 24.0 cells per ml: 225750 purity (%): 97.0 rna integrity number: 7.9 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: yes total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none	12.11041
GSM8083334	patient C3P1, after second course of MP, T cells	tissue: peripheral blood patient id: C3P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 10.1 cells per ml: 315000 purity (%): 98.6 rna integrity number: 8.3 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: worse total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none	12.12005
GSM8083335	patient C4P1, before first course of MP, B cells	tissue: peripheral blood patient id: C4P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 5.3 cells per ml: 336000 purity (%): 96.3 rna integrity number: 9.4 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis	12.11993
GSM8083336	patient C4P1, after first course of MP, B cells	tissue: peripheral blood patient id: C4P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.9 cells per ml: 1417500 purity (%): 96.1 rna integrity number: 8.7 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis	11.56191
GSM8083337	patient C4P2, before first course of MP, B cells	tissue: peripheral blood patient id: C4P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: NA cells per ml: 493500 purity (%): 94.2 rna integrity number: 8.2 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 7.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: yes fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	12.60277
GSM8083338	patient C4P2, after first course of MP, B cells	tissue: peripheral blood patient id: C4P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.4 cells per ml: 236250 purity (%): 42.7 rna integrity number: 8.1 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 6.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	10.80861

ID	GSE4386
Title	Transcriptomics in cardiac surgery
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM99229	H01_S_B1	male CABG patient, atrial tissue baseline before CABG surgery	419.6899458563333
GSM99235	H01_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	406.49547674033334
GSM99239	H02_P_B1	male CABG patient, atrial tissue baseline before CABG surgery	415.3280827556667
GSM99241	H02_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	347.2628255486666
GSM99244	H03_P_B1	male CABG patient, atrial tissue baseline before CABG surgery	437.203001955
GSM99246	H03_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	359.17754492599994
GSM99247	H04_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	480.47056651233333
GSM99249	H04_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	436.4306562046666
GSM99252	H05_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	497.52046048133326
GSM99253	H05_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	397.458526296
GSM99255	H06_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	278.3290125426667
GSM99257	H06_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	306.42304769833333
GSM99258	H07_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	507.4709398336667
GSM99259	H07_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	489.1519658923333
GSM99261	H08_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	570.5510369963333
GSM99265	H08_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	519.82668516
GSM99268	H09_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	358.04433855300005
GSM99271	H09_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	379.2667486193334
GSM99274	H10_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	339.587164984
GSM99277	H10_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	396.409243969
GSM99280	H11_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	548.4145354590001
GSM99282	H11_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	487.73978082499997
GSM99285	H12_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	473.4239625356666
GSM99287	H12_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	383.3869081806667
GSM99289	H13_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	504.1344104976667
GSM99290	H13_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	462.68812413866675
GSM99291	H14_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	417.42735666199997
GSM99292	H14_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	425.685822609
GSM99293	H15_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	408.2530014686667
GSM99294	H15_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	315.2906994623333
GSM99295	H16_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	271.879665483
GSM99296	H16_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	373.9577281089999
GSM99298	H17_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	626.9708825309999
GSM99299	H17_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	566.4483974646666
GSM99301	H18_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	426.62092702399997
GSM99302	H18_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	444.5646583916667
GSM99303	H19_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	385.8206251543333
GSM99304	H19_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	512.0840146646666
GSM99305	H20_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	526.1352032326666
GSM99306	H20_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	483.32611847766674

ID	GSE56256
Title	Influence of hexafluoro-2-propanol (HFIP) on lipopolysaccharides-induced inflammation in human microvascular endothelial cells of the lung
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM1357752	7_HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs	3326.5375000000004
GSM1357753	8_HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs	3801.7225
GSM1357754	9_HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs	3771.5150000000003
GSM1357755	4_LPS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs	3349.907
GSM1357756	5_LPS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs	3565.1715000000004
GSM1357757	6_LPS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs	2548.363
GSM1357758	11_LPS-HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs	2442.562
GSM1357759	12_LPS-HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs	3897.2035
GSM1357760	1_PBS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs	2776.605
GSM1357761	2_PBS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs	3117.721
GSM1357762	3_PBS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs	2987.6375

ID	GSE59526
Title	Affymetrix Chip data of the transcriptome of human clinical study for acupuncture mechanisms on rheumatoid arthritis
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM1438864	Peripheral blood mononuclear cells from AP group, Patient 2 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: before therapy patient id: 2	1062.6918921476665
GSM1438865	Peripheral blood mononuclear cells from AP group, Patient 3 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: before therapy patient id: 3	1124.8822076666668
GSM1438866	Peripheral blood mononuclear cells from AP group, Patient 6 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: before therapy patient id: 6	1105.7825691133332
GSM1438867	Peripheral blood mononuclear cells from AP group, Patient 8 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: before therapy patient id: 8	506.8706561066667
GSM1438868	Peripheral blood mononuclear cells from AP group, Patient 9 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: before therapy patient id: 9	548.9795034766667
GSM1438869	Peripheral blood mononuclear cells from MTX group, Patient 4 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: before therapy patient id: 4	765.0138689233335
GSM1438870	Peripheral blood mononuclear cells from MTX group, Patient 5 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: before therapy patient id: 5	876.8492941733334
GSM1438871	Peripheral blood mononuclear cells from MTX group, Patient 7 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: before therapy patient id: 7	549.5990630833334
GSM1438872	Peripheral blood mononuclear cells from Patient 1 after 2 weeks acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 1	1056.1583921553333
GSM1438873	Peripheral blood mononuclear cells from Patient 3 after 2 weeks acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 3	1011.3653911666667
GSM1438874	Peripheral blood mononuclear cells from Patient 1 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 1	607.6739767466667
GSM1438875	Peripheral blood mononuclear cells from Patient 2 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 2	851.4977489183334
GSM1438876	Peripheral blood mononuclear cells from Patient 6 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 6	846.4681683643333
GSM1438877	Peripheral blood mononuclear cells from Patient 8 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id:	715.38673337
GSM1438878	Peripheral blood mononuclear cells from Patient 9 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 9	722.6281734366667
GSM1438879	Peripheral blood mononuclear cells from Patient 4 after 3 months MTX therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: after 3 months therapy patient id: 4	672.48086581
GSM1438880	Peripheral blood mononuclear cells from Patient 5 after 3 months MTX therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: after 3 months therapy patient id: 5	650.0479387766667
GSM1438881	Peripheral blood mononuclear cells from Patient 7 after 3 months MTX therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: after 3 months therapy patient id: 7	883.3097118810001